Characteristic | NOWAC pilot study | |||
---|---|---|---|---|
Study population | PCR analyses | |||
Cases N (%) | Controls N (%) | Cases N (%) | Controls N (%) | |
Study subjects | 108 (100) | 44 (100) | 40 (100) | 20 (100) |
Age (years) | ||||
 ≤ 50 | 7 (6.5) | 1 (2.3) | 1 (2.5) | 1 (5.0) |
 > 50 | 101 (93.5) | 43 (97.7) | 39 (97.5) | 19 (95.0) |
Tumor grade | ||||
 1 | 34 (31.5) | – | 7 (17.5) | – |
 2 | 42 (38.9) | – | 17 (42.5) | – |
 3 | 28 (25.9) | – | 16 (40.0) | – |
 Unknown | 4 (3.7) |  | 0 (0) |  |
Tumor size (mm) | ||||
 0–10 | 23 (21.3) | – | 2 (5.0) | – |
 10–20 | 50 (46.3) | – | 24 (60.0) | – |
 > 20 | 34 (31.5) | – | 14 (35.0) | – |
 Unknown | 1 (0.9) |  | 0 (0) |  |
Lymph node status | ||||
 N0 | 73 (67.6) | – | 30 (75.0) | – |
 N+ | 34 (31.5) | – | 10 (25.0) | – |
 Unknown | 1 (0.9) | – | 0 (0) | – |
Hormone receptor status | ||||
 ER/PR positive | 81 (75.0) | – | 23 (57.5) | – |
 ER/PR negative | 27 (25.0) | – | 17 (42.5) | – |
 Unknown | 0 (0) | – | 0 (0) | – |
HER2 receptor status | ||||
 HER2 positive | 20 (18.5) | – | 15 (37.5) | – |
 HER2 negative | 86 (79.6) | – | 25 (62.5) | – |
 Unknown | 2 (1.9) | – | 0 (0) | – |
Molecular subtype | ||||
 Luminal A | 58 (53.7) | – | 12 (30.0) | – |
 Luminal B | 22 (20.4) | – | 11 (27.5) | – |
 HER2 positive | 9 (8.3) | – | 7 (17.5) | – |
 Triple-negative | 16 (14.8) | – | 10 (25.0) | – |
 Unknown | 3 (2.8) |  | 0 (0) |  |
Histological type | ||||
 Infiltrating carcinoma NST | 92 (85.2) | – | 35 (87.5) | – |
 Lobular carcinoma | 10 (9.3) | – | 3 (7.5) | – |
 Tubular | 3 (2.8) | – | 0 (0) | – |
 Other | 3 (2.8) | – | 2 (5.0) | – |